Kamran Hosseini, MD, PhD

Chief Executive Officer

Kamran Hosseini, MD, PhD has over 20 years of experience in the field of ophthalmology drug & device development. Most recently, as Site Lead & Chief Medical Officer at Insite Vision (a Sun Pharma company), he oversaw clinical, pre-clinical, CMC, manufacturing, regulatory affairs, and drug development programs. He led the approval of AzaSite in Canada & BromSite in USA. Prior to InSite, he was the resident expert and a member of the Ophthalmology Task Force of J&J and director of the ocular drug delivery program at Alza Corporation (a J&J company). He has over 20 patents in drug delivery (filed & issued) and has (co-)authored over 60 scientific & clinical publications.


Richard Lindstrom, MD

Director

Dr. Lindstrom is a founder, director and has been an attending surgeon at Minnesota Eye Consultants P.A., a provider of eye care services, since 1989. Dr. Lindstrom has served as a researcher, teacher, inventor, writer, lecturer and highly acclaimed physician and surgeon in the ophthalmology field. He has also served as a member of the board of directors of TearLab Corporation since 2010 and Ocular Therapeutix, Inc. since 2012. Dr. Lindstrom has also served as associate director of the Minnesota Lions Eye Bank since 1987 and he is a medical advisor for several medical device and pharmaceutical manufacturers and serves on the boards of several other privately-held life sciences companies. Dr. Lindstrom previously served as president of the International Society of Refractive Surgery from 1993 to 1994, the International Intraocular Implant Society from 2002 to 2004, the International Refractive Surgery Club from 2002 to 2004, and the American Society of Cataract and Refractive Surgery from 2007 to 2008. Dr. Lindstrom currently serves on the ASCRS Executive Committee and is a board member of the ASCRS Foundation. From 1980 to 1989, he served as a professor of ophthalmology at the University of Minnesota, where he is currently an adjunct professor emeritus. Dr. Lindstrom is also a board member of the University of Minnesota Foundation, chairing the Ophthalmology and Visual Neurosciences Division. Dr. Lindstrom holds a B.A. degree in Pre-Medical Studies, a B.S. degree in Medicine and an M.D. degree from the University of Minnesota. Dr. Lindstrom brings to the Board over 30 years of ophthalmology industry experience, as well extensive experience serving as a director of other companies.


Adrienne Graves, PhD

Director

Adrienne L. Graves, PhD is a visual scientist by training and a global industry leader in ophthalmology.  From 2002 to 2010, Dr. Graves was President and Chief Executive Officer of Santen Inc., the US arm of Japan’s largest ophthalmic pharmaceutical company. She joined Santen in 1995 as VP of Clinical Affairs to initiate clinical development in the US, and was responsible for 3 NDA approvals. She was promoted to Sr. VP of Worldwide Clinical Affairs (Japan, US, and Europe), and was subsequently named a global Corporate Officer and CEO of US operations. Prior to joining Santen, Dr. Graves spent nine years with Alcon Laboratories, Inc., beginning in 1986 as a Senior Scientist. She progressed through various roles, including Director of International Ophthalmology.  In 2015, Glaucoma Research Foundation presented The Catalyst Award to Dr. Graves in recognition of her outstanding leadership and many contributions to ophthalmology and for her dedicated service on the GRF Board of Directors. She currently serves on the Glaucoma Research Foundation Board’s Research Committee.  Dr. Graves co-founded Glaucoma 360 (Glaucoma Research Foundation) and Ophthalmic Women Leaders (OWL). She received her AB in Psychology with honors from Brown University, her PhD in Psychobiology from the University of Michigan, and she completed a postdoctoral fellowship in visual neuroscience at the University of Paris.

Dr. Graves currently serves as an Independent Director on the following corporate boards: Aerpio Therapeutics, Akorn, Inc., Encore Vision, Inc., Envisia Therapeutics, Nicox S.A., and TearLab Corporation. She is also a Director on the following Foundation Boards: American Society of Cataract and Refractive Surgery (ASCRS) Foundation, Glaucoma Research Foundation, American Academy of Ophthalmology (AAO) Foundation (Emeritus), Himalayan Cataract Project, Pan-American Ophthalmology Foundation, and KeepYourSight Foundation; she also serves on the Corporation Committee for the Brown University Medical School and the Advisory Board for Amach Capital Partners.


Lou Drapeau

Director

Louis Drapeau has served on numerous public company boards of directors.  He currently serves on the boards of AmpliPhi Biosciences and Avita Medical as well as Surface Pharmaceuticals, Inc.  Mr. Drapeau served with InSite Vision, Inc., a publicly traded ophthalmology drug development company, that was acquired in October 2015.  He was Chief Executive Officer of InSite Vision from November 2008 to December 2010 and Chief Financial Officer from November 2008.  Previous to InSite Vision, he served as Chief Financial Officer at Nektar Therapeutics, a publicly traded biopharmaceutical company, from January 2006 to August 2007.  Prior to Nektar, he served as Acting Chief Executive Officer from August 2004 to May 2005 for BioMarin Pharmaceutical.  He was also Chief Financial Officer of BioMarin from August 2002 to August 2005.   Previously, Mr. Drapeau was at Arthur Andersen for 30 years, including 19 years as an Audit Partner which included 12 years as Managing Partner.  Mr. Drapeau holds a B.S. in Mechanical Engineering and an M.B.A. from Stanford University.


Mark Baum, JD

Director

Mark L. Baum is the founder and CEO of Imprimis Pharmaceuticals whose mission is to provide patients and physicians with innovative and affordable ophthalmic drugs in the ocular surgery, glaucoma, and dry eye disease markets. Mr. Baum is also a founder and board member of Eton Pharmaceuticals and Surface Pharmaceuticals, as well as a board member and chairman of the audit committee of Ideal Power. Mr. Baum was named by Ernst & Young LLP as the 2017 Entrepreneur of the Year™ in the life sciences category for the San Diego region. Prior to Imprimis, as the founder of TBLF, LLC, a private investment fund, Mr. Baum made more than 200 investments into more than 40 private and public companies. In 1999, Mr. Baum founded YesRx, an HIV-focused pharmacy business. Mr. Baum’s advocacy for drug pricing and accessibility issues has been reflected as an Op-Ed contributor for the Wall Street Journal and through appearances on CBS, CNN, MSNBC, Fox Business, Bloomberg and Al Jazeera. Mr. Baum is a 1995 cum laude graduate of The University of Texas at Arlington and a 1997 graduate of California Western School of Law.